Adicet Bio, Inc. announced preclinical data highlighting ADI-270, an armored allogeneic “off-the-shelf” gamma delta CAR T cell therapy candidate targeting CD70+ cancers, at the 26th Annual Meeting of the American Society of Gene & Cell Therapy taking place from May 16-20, 2023, in Los Angeles, CA.
